- Home
- ACHV vs ADAP Comparison
ACHV vs ADAP Comparison
Compare ACHV & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- ADAP
- Stock Information
- Founded
- ACHV N/A
- ADAP 2008
- Country
- ACHV Canada
- ADAP United Kingdom
- Employees
- ACHV N/A
- ADAP N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- ADAP Health Care
- Exchange
- ACHV Nasdaq
- ADAP Nasdaq
- Market Cap
- ACHV 72.5M
- ADAP 71.6M
- IPO Year
- ACHV N/A
- ADAP 2015
- Fundamental
- Price
- ACHV $1.99
- ADAP $0.24
- Analyst Decision
- ACHV Strong Buy
- ADAP Strong Buy
- Analyst Count
- ACHV 3
- ADAP 5
- Target Price
- ACHV $14.33
- ADAP $1.83
- AVG Volume (30 Days)
- ACHV 193.4K
- ADAP 2.6M
- Earning Date
- ACHV 05-08-2025
- ADAP 05-14-2025
- Dividend Yield
- ACHV N/A
- ADAP N/A
- EPS Growth
- ACHV N/A
- ADAP N/A
- EPS
- ACHV N/A
- ADAP N/A
- Revenue
- ACHV N/A
- ADAP $178,032,000.00
- Revenue This Year
- ACHV N/A
- ADAP N/A
- Revenue Next Year
- ACHV N/A
- ADAP $65.49
- P/E Ratio
- ACHV N/A
- ADAP N/A
- Revenue Growth
- ACHV N/A
- ADAP 195.34
- 52 Week Low
- ACHV $1.84
- ADAP $0.20
- 52 Week High
- ACHV $5.59
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- ACHV 31.53
- ADAP 37.78
- Support Level
- ACHV $1.98
- ADAP $0.23
- Resistance Level
- ACHV $2.28
- ADAP $0.26
- Average True Range (ATR)
- ACHV 0.24
- ADAP 0.04
- MACD
- ACHV -0.02
- ADAP 0.01
- Stochastic Oscillator
- ACHV 15.62
- ADAP 31.85
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.